At a glance
- Originator GlaxoSmithKline
- Class Antineoplastics; Antirheumatics
- Mechanism of Action Collagenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 06 Dec 2000 Profile reviewed but no significant changes made
- 09 Mar 1999 No-Development-Reported for Rheumatic disorders in United Kingdom (Unknown route)
- 29 Aug 1996 New profile